Novo Nordisk's Summer of Setbacks: Buybacks and Better Guidance Can't Quiet Pipeline Doubts
Published on 08/12/2026 at 14:21 | Redaktion boerse-global.de
The arithmetic of Novo Nordisk's second quarter looks encouraging on paper. Adjusted sales climbed 7 percent on a CER basis, adjusted operating profit rose 11 percent, and management lifted its full-year outlook to a range of 0 to minus 6 percent growth in both revenue and operating profit — a clear improvement from the previous minus 4 to minus 12 percent forecast.
Yet the market's response was anything but celebratory. US-listed shares fell after the release, and the stock has continued to drift lower since, closing at €39.83 on the day of the announcement with a 2.85 percent decline. Investors, it seems, are less interested in what Novo Nordisk is selling today than in what it might — or might not — be selling tomorrow.
That skepticism has a name: the pipeline.
A String of Clinical Setbacks
The most recent blow came in late July, when the experimental inflammation drug Ziltivekimab failed its late-stage ZEUS trial, missing the goal of reducing major cardiovascular events. The setback was a significant dent in the company's ambition to diversify beyond obesity and diabetes care. Copenhagen-listed shares tumbled 7.3 percent on the news, with the Wall Street Journal reporting a decline of nearly 8 percent in Denmark and more than 9 percent for the US-traded shares.
Then came the second-quarter numbers, which carried their own disappointment. The company booked a non-cash impairment charge of 6.3 billion Danish kroner on intangible pipeline assets — including the candidate Monlunabant — dragging reported operating profit down 16 percent on a CER basis. A 2.6 billion kroner release of provisions in the year-ago quarter compounded the comparison.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The oral Wegovy tablet, meanwhile, generated sales that fell short of analyst expectations. The company did highlight that the pill has surpassed 5 million cumulative prescriptions in the US since launch — evidence that demand for a non-injectable option is real — but the milestone did little to offset the underwhelming revenue figures.
A Tale of Two Rivals
The contrast with Eli Lilly could hardly be starker. On the same day Novo Nordisk's shares lost more than 4 percent despite the raised guidance, Lilly advanced over 7 percent following its own better-received quarterly results. The market, in other words, is increasingly treating the two obesity-drug rivals as a zero-sum contest — and currently awarding the clearer victory to the American challenger.
Reuters and the Wall Street Journal both pointed to the disappointing Wegovy pill sales and pipeline concerns as the primary drivers of the muted response to Novo Nordisk's improved outlook. Regulatory and pricing risks in the US market also weighed on investor sentiment around the earnings release.
The Buyback Machine Keeps Running
Amid the turbulence, Novo Nordisk's capital return program has continued without interruption. Between August 4 and 7, the company repurchased an additional 820,000 B-shares, bringing the current tranche to 13,125,000 B-shares acquired for 3,980,067,920 kroner. Since the start of the program on February 4 — which has a total volume of up to 15 billion kroner — Novo Nordisk has bought back 27,884,179 B-shares for 7,780,067,909 kroner.
Shareholders also have an interim dividend of 3.75 kroner per A- and B-share to look forward to. The ex-dividend date falls on August 14 for the Danish shares and August 17 for the ADRs, with payment scheduled for August 18 and August 25, respectively.
First-half figures underscore the company's cash-generating strength: revenue of 148.6 billion kroner and free cash flow of 42.5 billion kroner. That financial firepower gives management room to pursue what CEO Mike Doustdar has described as targeted "bolt-on acquisitions" to fill portfolio gaps, alongside an accelerated R&D effort.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Where the Stock Stands
The share price has been hovering near its 50-day moving average of €41.16, with the relative strength index at 46.7 — a neutral reading that suggests no clear directional bias from a technical standpoint. At €41.00, the stock sits roughly 25 percent below its 52-week high of €54.86, reached on January 23. Year-to-date, the shares are down 6.87 percent, though the weekly picture shows a gain of 5.90 percent and the monthly view remains negative at minus 5.10 percent.
For bulls, the valuation argument is straightforward: with the shares trading well off their highs and the underlying business still generating substantial cash, the risk-reward profile looks attractive — provided the pipeline concerns prove overblown. For bears, the impairment on Monlunabant is not an isolated event but part of a pattern of development setbacks, and the raised guidance could be dismissed as a short-term fix that fails to address the structural slowdown in growth.
The coming months will test whether Doustdar can translate his promises of faster research and selective dealmaking into concrete transactions and clinical progress. Until then, the stock appears destined to oscillate between the comfort of a robust balance sheet and the anxiety of an uncertain product pipeline.
Ad
Novo Nordisk Stock: New Analysis - 12 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
